BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Can Edwards Lifesciences Corporation (EW)'s Medical Device Leader Bounce Back?


12/5/2012 9:13:20 AM

It seemed like nothing but blue skies ahead for Edwards Lifesciences (NYSE: EW ) back in early October. Shares were up more than 50% year-to-date and traded at 52-week highs. Then the sky fell. On Oct. 9, the company announced that it missed sales forecasts for the third quarter. The stock fell 18%, the largest one-day drop in 12 years. Edwards shares haven't been able to rebound much since that point. However, the company announced solid 2013 forecasts today. Shares climbed around 5% on the news. Can Edwards Lifesciences bounce back to its previous highs? Let's take a look. Springboards: Edwards projects sales growth of 13% to 16% and earnings growth of 25% in 2013. The company's Sapien transcatheter heart valve stands to be one of the biggest springboards to achieve this growth. Management expects global sales growth to be in the range of 30% to 45% for its transcatheter heart valve business. That rate would put total sales for the unit in the $710 million to $790 million range. The Intuity surgical heart valve system could be another catalyst for growth. Edwards plans to launch the product in Europe during 2013. The company projects sales of $800 to $840 million next year for its surgical heart valves, which reflects growth of 4% to 6% compared to 2012. Critical care monitoring systems should contribute to growth, although to a lesser extent than other products. Edwards projects that advanced monitoring systems, including two new products for non-invasive monitoring and glucose monitoring, will help grow critical care sales by 4% to 6% in 2013. This growth would mean total critical care sales of $560 million to $600 million. Bounce-busters: What could keep the stock from bouncing back? Several potential bounce-busters could emerge. Europe could continue to be problematic. Other medical device companies have already experienced headwinds resulting from the implementation of European austerity programs. For example, Intuitive Surgical (Nasdaq: ISRG ) cited European challenges as a factor in its disappointing third-quarter results. Edwards encountered similar problems last quarter. Europe represented nearly 31% of Edwards' total sales in the first nine months of 2012.

Read at Fool

Fool
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES